Ask AI
Expert guidance in chronic obesity management

CE / CME

Chronic Obesity Management: Expert Perspectives on Long-term Weight Loss Support and Monitoring

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: September 25, 2025

Expiration: September 24, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Martins C, Dutton GR, Hunter GR, et al. Revisiting the Compensatory Theory as an explanatory model for relapse in obesity management. Am J Clin Nutr. 2020;112:1170-1179.
  2. Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018;102:183-197.
  3. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30:2049-2057.
  4. Ard J. Lee C, Cao D, et al. Sustained weight reduction by thresholds in adults with obesity and prediabetes treated with tirzepatide over 176 weeks (SURMOUNT-1). Presented at: 2025 American Diabetes Association Scientific Sessions; June 20-23, 2025. Abstract 144-OR.
  5. Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47:1873-1888.
  6. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22.
  7. Liu L, Li Z, Ye W, et al. Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis. EClinicalMedicine. 2024;79:103020.
  8. Wu H, Yang W, Guo T, et al. Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications. BMC Medicine. 2025;23:398.
  9. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-1564.
  10. Aronne LJ. Tirzepatide for maintenance of weight reduction in adults with obesity-reply. JAMA. 2024;331:1676.
  11. Semaglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk; 2025.
  12. Tirzepatide [prescribing information]. Indianapolis, IN: Lilly; 2025.
  13. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-2232.
  14. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-2099.
  15. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391:1193-1205
  16. Montesi L, El Ghoch M, Brodosi L, et al. Long-term weight loss maintenance for obesity: a multidisciplinary approach. Diabetes Metab Syndr Obes. 2016 Feb 26;9:37-46.
  17. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221-262.
  18. Palad CJ, Stanford FC. Use of people-first language with regard to obesity. Am J Clin Nutr. 2018;108:201-203.
  19. Grudniewicz A, Gray CS, Boeckxstaens P, et al. Operationalizing the chronic care model with goal-oriented care. Patient. 2023;16:569-578.
  20. Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75:235-251.